Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 1Anemia 1

Interventions

Specimen Handling 5X-Rays 3Magnetic Resonance Spectroscopy 3Immunoglobulin G 3Disulfides 3pembrolizumab 2cabozantinib 2Taxes 2Sunitinib 2Rituximab 2Phantoms, Imaging 2Paclitaxel 2Nivolumab 2Cyclophosphamide 2Carboplatin 2CT-P10 2Biopsy 2Bevacizumab 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1relatlimab 1prednylidene 1pertuzumab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1pegaspargase 1palbociclib 1osimertinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Has announcements × Pharmacogenomic Testing × Clear all
NCT02048813 2026-05-29

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
529 enrolled 12 charts 1 FDA
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡